Intercept Pharmaceuticals Inc
NASDAQ:ICPT
Intercept Pharmaceuticals Inc
Total Liabilities & Equity
Intercept Pharmaceuticals Inc
Total Liabilities & Equity Peer Comparison
Competitive Total Liabilities & Equity Analysis
Latest Figures & CAGR of Competitors
Company | Total Liabilities & Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Intercept Pharmaceuticals Inc
NASDAQ:ICPT
|
Total Liabilities & Equity
$393.2m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities & Equity
$148.9B
|
CAGR 3-Years
0%
|
CAGR 5-Years
21%
|
CAGR 10-Years
18%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities & Equity
$56.3B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities & Equity
$93B
|
CAGR 3-Years
14%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities & Equity
$23.9B
|
CAGR 3-Years
25%
|
CAGR 5-Years
30%
|
CAGR 10-Years
27%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities & Equity
$34.4B
|
CAGR 3-Years
25%
|
CAGR 5-Years
22%
|
CAGR 10-Years
27%
|
See Also
What is Intercept Pharmaceuticals Inc's Total Liabilities & Equity?
Total Liabilities & Equity
393.2m
USD
Based on the financial report for Sep 30, 2023, Intercept Pharmaceuticals Inc's Total Liabilities & Equity amounts to 393.2m USD.
What is Intercept Pharmaceuticals Inc's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 10Y
9%
Over the last year, the Total Liabilities & Equity growth was -30%. The average annual Total Liabilities & Equity growth rates for Intercept Pharmaceuticals Inc have been -13% over the past three years , -7% over the past five years , and 9% over the past ten years .